Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06111443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

StatusActive, Not Recruiting
PhasePhase 2/3
Started2023-12-01
View on ClinicalTrials.gov ↗

Amendment history

2023-12-19
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v1
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2023-10-26
Original filing
The goal of this clinical trial is to test the effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation. The main questions it aims to answer are: • If Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias \[atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT)\] greater than 30 seconds during one-year follow-up after catheter ablation. Participants will receive Dapagliflozin (FORXIGA) 10 milligram (mg) once a day (QD) for 3 months after catheter ablation of atrial fibrillation. Researchers will compare patients who receive usual care to see if Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias (AF/AFL/AT) during one-year follow-up after catheter ablation.
Trial Details
NCT Number NCT06111443
Lead Sponsor Chang Gung Memorial Hospital
Conditions Atrial Fibrillation Recurrent, Catheter Ablation
Enrollment 196 participants
Start Date 2023-12-01
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2023-12-21